Loading...

Anchiano Therapeutics

OTCPK:BCNL.F
Snowflake Description

Imperfect balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BCNL.F
OTCPK
₪143M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. The last earnings update was 49 days ago. More info.


Add to Portfolio Compare Print
BCNL.F Share Price and Events
7 Day Returns
0%
OTCPK:BCNL.F
-2.7%
US Biotechs
-2.3%
US Market
1 Year Returns
-
OTCPK:BCNL.F
-3.5%
US Biotechs
4.1%
US Market
BCNL.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Anchiano Therapeutics (BCNL.F) 0% 0% 0% - - -
US Biotechs -2.7% -6.1% -2.3% -3.5% 11.4% 15%
US Market -2.3% -0.6% 6% 4.1% 39.4% 44.7%
1 Year Return vs Industry and Market
  • No trading data on BCNL.F.
  • No trading data on BCNL.F.
Price Volatility
BCNL.F
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Anchiano Therapeutics's competitors could be found in our database.

Value

 Is Anchiano Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Anchiano Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Anchiano Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Anchiano Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $2.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Anchiano Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Anchiano Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:BCNL.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.05
TASE:ANCN Share Price ** TASE (2019-02-12) in ILS ₪4.2
TASE:ANCN Share Price converted to USD reporting currency Exchange rate (ILS/ USD) 0.281 $1.18
United States of America Biotechs Industry PE Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 19.6x
United States of America Market PE Ratio Median Figure of 3,086 Publicly-Listed Companies 18.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Anchiano Therapeutics.

OTCPK:BCNL.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TASE:ANCN Share Price ÷ EPS (both in USD)

= 1.18 ÷ -1.05

-1.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Anchiano Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Anchiano Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Anchiano Therapeutics's expected growth come at a high price?
Raw Data
OTCPK:BCNL.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-23.8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.2x
United States of America Market PEG Ratio Median Figure of 2,114 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Anchiano Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Anchiano Therapeutics's assets?
Raw Data
OTCPK:BCNL.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-0.07
TASE:ANCN Share Price * TASE (2019-02-12) in ILS ₪4.2
TASE:ANCN Share Price converted to USD reporting currency Exchange rate (ILS/ USD) 0.281 $1.18
United States of America Biotechs Industry PB Ratio Median Figure of 415 Publicly-Listed Biotechs Companies 3.17x
United States of America Market PB Ratio Median Figure of 5,198 Publicly-Listed Companies 1.87x
OTCPK:BCNL.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TASE:ANCN Share Price ÷ Book Value per Share (both in USD)

= 1.18 ÷ -0.07

-16.85x

* Primary Listing of Anchiano Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Anchiano Therapeutics has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. Take a look at our analysis of BCNL.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Anchiano Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Anchiano Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Anchiano Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-23.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Anchiano Therapeutics expected to grow at an attractive rate?
  • Unable to compare Anchiano Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Anchiano Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Anchiano Therapeutics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:BCNL.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:BCNL.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -23.8%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:BCNL.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:BCNL.F Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 0 1
2020-12-31 0 -21 1
2019-12-31 0 -16 1
OTCPK:BCNL.F Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -15 -13
2018-09-30 -13 -13
2018-06-30 -8 -13
2018-03-31 -10 -11
2017-12-31 -9 -10
2017-09-30 -8 -9
2017-06-30 -7 -9
2017-03-31 -4 -7
2016-12-31 -4 -5
2016-09-30 -4 -5
2016-06-30 -4 -4
2016-03-31 -7 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Anchiano Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Anchiano Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:BCNL.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Anchiano Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:BCNL.F Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31
OTCPK:BCNL.F Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.05
2018-09-30 -1.19
2018-06-30 -1.30
2018-03-31 -1.17
2017-12-31 -1.09
2017-09-30 -1.12
2017-06-30 -1.25
2017-03-31 -1.07
2016-12-31 -0.87
2016-09-30 -0.95
2016-06-30 -0.79
2016-03-31 -1.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Anchiano Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Anchiano Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Anchiano Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Anchiano Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Anchiano Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Anchiano Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Anchiano Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Anchiano Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Anchiano Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Anchiano Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:BCNL.F Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -13.28 5.49 7.56
2018-09-30 -13.31 5.19 6.65
2018-06-30 -12.53 4.81 6.36
2018-03-31 -11.18 3.34 7.53
2017-12-31 -9.81 3.16 6.23
2017-09-30 -9.37 3.10 6.00
2017-06-30 -9.02 3.01 5.64
2017-03-31 -6.51 2.93 3.23
2016-12-31 -4.74 2.26 2.38
2016-09-30 -4.67 1.80 2.62
2016-06-30 -3.88 1.43 2.41
2016-03-31 -5.77 1.13 4.57
2015-12-31 -7.48 1.14 5.97
2015-09-30 -7.64 1.05 6.37
2015-06-30 -9.05 1.15 7.64
2015-03-31 -6.92 1.05 5.68
2014-12-31 -5.52 1.09 4.53
2014-09-30 -5.61 1.27 4.33
2014-06-30 -5.75 1.29 4.38
2014-03-31 -5.66 1.31 4.54
2013-12-31 -6.05 1.32 4.17
2013-09-30 -6.18 1.34 4.28
2013-06-30 -5.14 1.27 3.14
2013-03-31 -7.25 1.39 3.50
2012-12-31 -6.48 1.51 3.69
2012-09-30 -6.35 1.44 3.64
2012-06-30 -6.16 1.62 4.11

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Anchiano Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Anchiano Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Anchiano Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Anchiano Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Anchiano Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Anchiano Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Anchiano Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Anchiano Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Anchiano Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Anchiano Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Anchiano Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Anchiano Therapeutics Company Filings, last reported 4 months ago.

OTCPK:BCNL.F Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -1.09 0.00 7.52
2018-09-30 0.23 0.00 10.91
2018-06-30 2.59 0.00 19.49
2018-03-31 -3.93 0.00 0.67
2017-12-31 -0.61 0.00 1.45
2017-09-30 1.12 0.00 3.33
2017-06-30 2.91 0.00 5.04
2017-03-31 1.34 0.00 3.45
2016-12-31 3.29 0.00 4.56
2016-09-30 4.06 0.00 5.23
2016-06-30 0.85 0.00 1.04
2016-03-31 1.43 0.00 1.12
2015-12-31 2.14 0.00 2.36
2015-09-30 3.32 0.00 3.94
2015-06-30 4.19 0.00 5.25
2015-03-31 6.75 0.00 7.76
2014-12-31 4.98 0.00 5.67
2014-09-30 6.79 0.00 8.67
2014-06-30 1.79 0.00 3.02
2014-03-31 3.03 0.00 4.23
2013-12-31 1.71 0.00 2.43
2013-09-30 2.97 0.00 4.17
2013-06-30 3.64 0.00 4.65
2013-03-31 -0.65 0.00 1.31
2012-12-31 0.88 0.00 2.10
2012-09-30 -1.74 0.77 0.45
2012-06-30 -4.65 3.42 0.37
  • Anchiano Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Anchiano Therapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Anchiano Therapeutics has less than a year of cash runway based on current free cash flow.
  • Anchiano Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 34.4% each year.
X
Financial health checks
We assess Anchiano Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Anchiano Therapeutics has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Anchiano Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Anchiano Therapeutics dividends.
If you bought $2,000 of Anchiano Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Anchiano Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Anchiano Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:BCNL.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1998 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:BCNL.F Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Anchiano Therapeutics has not reported any payouts.
  • Unable to verify if Anchiano Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Anchiano Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Anchiano Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Anchiano Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Anchiano Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Anchiano Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Anchiano Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Frank Haluska
COMPENSATION $2,091,000
AGE 59
TENURE AS CEO 2.6 years
CEO Bio

Dr. Frank G. Haluska, M.D. Ph.D., serves as President and Chief Executive Officer at BioCancell Ltd. He also serves as Chief Executive Officer at Anchiano Therapeutics Ltd since October 2016 and also serves as its Director. He serves as the President at Anchiano Therapeutics Ltd. He currently serves on the board of at Vedantra Pharmaceuticals, Inc. Dr. Haluska served as the Chief Medical Officer of Ariad Haluska Inc., since June 2010 until May 6, 2016 and served as its Senior Vice President of Clinical R&D since January 2012 until May 6, 2016. Dr. Haluska served as Vice President of Clinical Research & Development at Ariad Pharmaceuticals Inc. since June 2010. He served as Senior Medical Director of Ariad Pharmaceuticals Inc. since November 2007 until July 2010. He is a recognized authority on the targeted therapy of kinase abnormalities in solid tumors. Most recently, he served as a senior faculty Member in the departments of medicine and genetics at Tufts University School of Medicine, where he served as Clinical Director and Deputy Director of the Tufts-New England Medical Center Cancer Center. He is also major in the Medical Corps of the United States Air Force and the Massachusetts Air National Guard. Dr. Haluska has to ARIAD fifteen years of experience in medical research and clinical oncology at centers of excellence, including the Dana-Farber Cancer Institute and Massachusetts General Hospital Cancer Center. He received his M.D. and Ph.D. from the University Of Pennsylvania School Of Medicine and his A.B. from Harvard University. He did postgraduate training at Massachusetts General Hospital, the Dana-Farber Cancer Institute and the Massachusetts Institute of Technology.

CEO Compensation
  • Frank's compensation has increased whilst company is loss making.
  • Frank's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Anchiano Therapeutics management team in years:

2.6
Average Tenure
54.5
Average Age
  • The tenure for the Anchiano Therapeutics management team is about average.
Management Team

Frank Haluska

TITLE
President
COMPENSATION
$2M
AGE
59
TENURE
2.6 yrs

Jonathan Burgin

TITLE
CFO & COO
COMPENSATION
$332K
AGE
57
TENURE
2.6 yrs

Ron Knickerbocker

TITLE
Senior Vice President of Clinical Development & Data Sciences
COMPENSATION
$493K
AGE
52
TENURE
1.2 yrs

Abraham Hochberg

TITLE
Co-Founder & Chief Scientific Officer
COMPENSATION
$471K
AGE
80
TENURE
15.3 yrs

David Kerstein

TITLE
Chief Medical Officer
AGE
35
TENURE
0.5 yrs

Avraham Hampel

TITLE
Company Secretary

Or Dolev

TITLE
Controller
COMPENSATION
$122K
AGE
40
TENURE
10.7 yrs
Board of Directors Tenure

Average tenure and age of the Anchiano Therapeutics board of directors in years:

1.7
Average Tenure
66
Average Age
  • The average tenure for the Anchiano Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Steve Hoffman

TITLE
Chairman of the Board
AGE
64
TENURE
0.5 yrs

Frank Haluska

TITLE
President
COMPENSATION
$2M
AGE
59

Hermona Soreq

TITLE
Member of Scientific Advisory Board

Yaakov Naparstek

TITLE
Member of Scientific Advisory Board

J. Ciechanover

TITLE
Member of Scientific Advisory Board
AGE
71

Yechezkel Barenholz

TITLE
Member of Scientific Advisory Board
AGE
76

Mark Tykocinski

TITLE
Member of the Scientific Advisory Board

Roger Kornberg

TITLE
Member of Scientific Advisory Board
AGE
71

Ruti Alon

TITLE
External Director
AGE
66
TENURE
1.7 yrs

Larry Howard

TITLE
Director
AGE
65
TENURE
2.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Anchiano Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Anchiano Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Jerusalem, Israel.

Details
Name: Anchiano Therapeutics Ltd
BCNL.F
Exchange: OTCPK
Founded: 2004
₪40,211,004
34,102,227
Website: http://www.anchiano.com
Address: Anchiano Therapeutics Ltd
1/3 High-Tech Park,
Givat Ram,
Jerusalem,
9139102,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TASE ANCN New Common Shares The Tel-Aviv Stock Exchange IL ILS 27. Feb 2012
OTCPK BCNL.F New Common Shares Pink Sheets LLC US USD 27. Feb 2012
NasdaqCM ANCN SPONSORED ADS Nasdaq Capital Market US USD 12. Feb 2019
Number of employees
Current staff
Staff numbers
19
Anchiano Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/13 01:02
End of day share price update: 2019/02/12 00:00
Last estimates confirmation: 2019/03/13
Last earnings filing: 2019/03/25
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.